Interferon (IFN-a) enhances the activity of 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer although the mechanism is not understood. We have investigated the effect of this combination on cellular immunity and compared this with standard therapy of 5-FU/L-leucovorin, in Poon et al., 1989) .
Interferon (IFN-a) enhances the activity of 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer although the mechanism is not understood. We have investigated the effect of this combination on cellular immunity and compared this with standard therapy of 5-FU/L-leucovorin, in 24 patients with advanced colorectal cancer. This study has demonstrated an enhancement of the cellular immune response m patients given 5-FU/IFN-a with augmentation of natural killer (NK) cel function and abrogation of 5-FU-induced suppression of lymphokine-activated killer (LAK) cell activity.
The combination of 5-fluorouracil (5-FU) and alpha interferon (IFN-a) is used increasingly in the treatment of advanced colorectal cancer. The initial phase II trial using this combination achieved objective responses in 60% of patients (Wadler et al., 1989) and, although a large phase Ill study failed to demonstrate such impressive results (Kocha, 1993) , they were, nevertheless similar to results with 5-FU and L-leucovorin. 5-FU and L-leucovorin is considered the standard treatment for advanced colorectal cancer, having achieved partial response rates in approximately 40% of patients with modest survival benefit (Petrelli et al., 1989; Poon et al., 1989) .
The mechanism by which IFN-a modulates the activity of 5-FU is unknown. In vitro cytoxicity studies using gastrointestinal cell lines how that interferon acts synergistically with 5-FU (Wadler et al., 1990) . It may be acting as an antiproliferative agent, either by biochemically modulating the effect of 5-FU or by some other mechanism. While other reports suggest that interferon alters the pharmacokinetics of 5-FU (Grem et al., 1991; Schuller et al., 1992) we have demonstrated that the steady-state plasma levels of 5-FU during two 5-day infusions, with and without IFN-a in the same patients, showed no significant differences (Pitman et al., 1993) .
Another possibility is that IFN-a may be acting through an immunological mechanism. It is known to augment natural killer (NK) cell activity, and it up-regulates expression of both class I MHC antigen and tumour-associated antigen in tumours (Trincheri et al., 1985) (Erlichman et al., 1988) . There were no differences between the study and control groups in terms of age, sex, burden or distribution of disease or performance status.
Twnour assessment
Serial computerised tomographic (CT) scanning was performed within 2 weeks prior to starting treatment, and at 8 weekly intervals thereafter to assess response. Tumour response was graded in accordance with WHO criteria as described in WHO (1979) .
Immunological studies 
Reslts Patient outcome
Response to treatment is shown in Table I . There were no complete responses in either group, and no statistically significnt differences in the number of partial responders: 1/9 in the control group and 5/14 in the IFN-a-treated group.
Treatment-related complications Treatment was tolerated well in both treatment groups, with no dose reduction or interruption in therapy necessary. All patients who entered the study were evaluable.
Lymphocyte function analysis Figure 1 demonstrates the percentage change in NK-cel function between the two treatment groups. NK-cell function (arbitrary units) was significantly reduced in the control group following the first week of chemotherapy from 151.7 ± 19.6 to 121.3 ± 16.7. The level of activity failed to return to pretreatment values prior to the next cycle of therapy (122.9 ± 17.9). Using the summary analysis described, the depression in NK-cell activity was significant (P<0.02). In contrast, in those patients receiving IFN-x with 5-FU, NK-cell activity was augmented, incrang consistently from a baseline of 117.0 ± 12.9 to 123.7 ± 14.8 after I week and to 183.0 ± 16.9 after 26-28 weeks (P<0.05). There was a marked difference between the two groups over the first 12 weeks of treatment (P<0.01). NK-cxll activity was seen to vary in relation to patient outcome, as shown in Figure 2 .
The percentage change in LAK-cell generation against the DAUDI target is shown in Figure 3 . As with NK-ceUl activity, LAK-cell function was reduced following treatment with 5-FU an L-leucovorin, from a pretreatment value of 265.4 ± 18.8 to 170.1 ± 30.2. Again activity remained reduced prior to the next treatment cycle, 201.4 ± 23.4, although in the longer term LAK-cell activity did return to pretreatment levels. The depression in the LAK-cell activity in the first 10 weeks of treatment was statistically significant (P<0.02). In contrast, treatment with 5-FU and IFN-a resulted in no such fall in LAK-cell generative capacity.
Lymphocyte phenotypic analysis
We failed to show any changes in the phenotypic pattern of peripheral blood lymphocytes throughout our monitoring period for both groups of patients (results not shown). Numbers of circulating lymphocytes were, however, reduced in those patients receiving IFN-x but not L-leucovonn (P<0.01) (Figure 4 ). This study demonstrates that 5-FU combined with L-leucovorin, the most widely used modulated 5-FU regimen, has a predominantly immunosuppressive effect. Both NK-and LAK-cell activity were diminished after the first cycle of treatment and did not return to the baseline level before the next cycle. The NK-cell activity remained suppressed compared with that in the 5-FU/IFN-a-treated group for a prolonged period. By contrast, the interferon-treated group showed no suppression of NK-or LAK-ell activity, and NK-cell activity was augmented. Fugwe 2 The percentage change in natural killer (NK) cell activity in all the patients in this study in relation to response to chemotherapy. NK activity was depressed in patients with progressive disease (P<0.05). A, Partial response; 0, stable disease; 0, progressive disease.
The NK-cell activity appears to be diminished in patients who develop progressive disease. This effect is predominantly due to the maintenance or enhancement of NK-cell activity in the group receiving 5-FU and IFN-m; the one responder in the group given 5-FU with L-leucovorin demonstrated quite marked depression of NK-cell activity. One possible explanation for this observation is that NK-cell activity simply reflects tumour burden. It is well known that patients with colorectal cancer are immunosuppressed and that this suppression is greater with a large tumour load (Monson et al., 1986) . Thus, as the disease progresses, it may be expected that there is deterioration in parameters that reflect immune function. Similarly, as a patient's tumour burden decreases it could be that there is an improvement in NK-cell activity. This possible explanation is made less likely in view of the immunosuppression observed in the control group given 5-FU/L-leucovorin, even in those who respond. Similarly, the minor differences in the 5-FU schedules between the two regimens also seem unlikely to explain the difference. tumour cells in vivo. As such, their principal activity is against tumours of haematological origin as there is little evidence that they have significant activity against solid organ malignancies (Goldstein et al., 1986 (Trincheri et al., 1985) . It is widely accepted that a lymphocytic infiltrate has favourable prognostic significance in colorectal tumours, hence there is prima facie evidence of a role for the immune system in the control of this malignancy. Treatment with 5-FU/IFN-a resulted in a relative lymphopenia when compared with 5-FU/L-leucovonn. This is a well-recognised effect of IFN-x and may be as a result of lymphocyte sequestration in peripheral sites, including potentially tumour tissue. Neither treatment had any effect on the lymphocyte subset analysis at any point in the study. This is T X-.Iill of particular interest with regard to the CD16 marker which labels NK cells. The fact that this marker remained unchanged indicates that any enhancement in NK-cell activity seen in the patients given IFN-a is due to the enhancement of the individual cells' killing ability rather than an expansion of cell numbers.
These studies do not establish that the enhanced efficacy of the 5-FU/IFN-a combination is an immunological one. Other possible mechanisms, such as an antiproliferative effect of IFN-a or the possibility that the cytokine may biochemically modulate 5-FU, warrant consideration. However, this study has established that some aspects of cellular immunity are maintained or enhanced in patients treated with 5-FU/IFN-a, in contrast to the control group. This may reflect a general increase in immune competence in these patients. Histological examination of 5-FU/IFN-a-treated metastases and the typing of any lymphocytic infiltrate may be required to investigate this possibility further.
